CEO Silviu Itescu explains how Mesoblast changes a disease that is fatal 70% or 90% to a disease that can be cured.

First please introduce your firm and your coverage. You recently said that this is a very problematic market. Why so? What prompts the change in your outlook? Dr. Brozak: I am President of WBB ...

Please provide an overview of your coverage and the subsectors, cap sizes, and primary names that you follow. Mr. Beatty: I cover biotech. And within biotech, most of my coverage is within the ...

Please give me an overview of the company and its services. Mr. Gonen: MediWound is a global leader in next generation enzymatic therapeutics for tissue repair. Our core active pharmaceutical ...

The big news is that the Fed cut rates by 50 basis points yesterday, and the market is dramatically rising. How is your coverage space looking? Dr. Phipps: Well, admittedly, the XBI, which is the ETF ...

So let’s start with a brief history of the company and its mission. Mr. Pilcher: Sure. So Neuren is an interesting company, which has had a long history and a couple of incarnations. Twenty years ago ...

We spoke about two years ago. How would you compare today’s market to back then? Mr. Vandermosten: Two years ago would have been fall 2022, and I think we had seen about a year of pullback in the life ...

Could you tell me about the company? Mr. Keddie: CompuMed is kind of a unique space. We’re in the telemedicine space. We started out, actually, in the early days, building echocardiogram devices, and ...

Could you tell me about Premier? Mr. Alkire: Sure. Premier is a health care improvement company. We have two different segments to our business. We have a supply chain segment and a performance ...

It’s been a few years since you spoke with The Wall Street Transcript. So, let’s start with a brief overview and history of the company. Dr. Itescu: Sure. So, we’re a mature company. We’re listed on ...

Mason D. King, CFA, is a Principal, Vice President, Director of Public Equity Investment Strategies, and Portfolio Manager at Luther King Capital Management. He joined the firm in 2004. Earlier ...